268 related articles for article (PubMed ID: 35738437)
1. Biologics in eosinophilic gastrointestinal diseases.
Dellon ES; Spergel JM
Ann Allergy Asthma Immunol; 2023 Jan; 130(1):21-27. PubMed ID: 35738437
[TBL] [Abstract][Full Text] [Related]
2. The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs.
Ridolo E; Barone A; Ottoni M; Peveri S; Montagni M; Nicoletta F
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338983
[TBL] [Abstract][Full Text] [Related]
3. Current and Novel Therapies for Eosinophilic Gastrointestinal Diseases.
Marasco G; Visaggi P; Vassallo M; Fiocca M; Cremon C; Barbaro MR; De Bortoli N; Bellini M; Stanghellini V; Savarino EV; Barbara G
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894846
[TBL] [Abstract][Full Text] [Related]
4. Benralizumab Completely Depletes Gastrointestinal Tissue Eosinophils and Improves Symptoms in Eosinophilic Gastrointestinal Disease.
Kuang FL; De Melo MS; Makiya M; Kumar S; Brown T; Wetzler L; Ware JM; Khoury P; Collins MH; Quezado M; Pittaluga S; Klion AD
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1598-1605.e2. PubMed ID: 35283330
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab Can Induce Remission of Eosinophilic Gastritis and Duodenitis: A Retrospective Case Series.
Sia T; Bacchus L; Tanaka R; Khuda R; Mallik S; Leung J
Clin Transl Gastroenterol; 2024 Jan; 15(1):e00646. PubMed ID: 37753954
[TBL] [Abstract][Full Text] [Related]
6. Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases.
Low EE; Dellon ES
Aliment Pharmacol Ther; 2024 Feb; 59(3):322-340. PubMed ID: 38135920
[TBL] [Abstract][Full Text] [Related]
7. Biological therapies for eosinophilic gastrointestinal diseases.
Wechsler JB; Hirano I
J Allergy Clin Immunol; 2018 Jul; 142(1):24-31.e2. PubMed ID: 29859203
[TBL] [Abstract][Full Text] [Related]
8. Biologic Therapies Targeting Eosinophilic Gastrointestinal Diseases.
Oshima T
Intern Med; 2023 Dec; 62(23):3429-3430. PubMed ID: 37081678
[No Abstract] [Full Text] [Related]
9. Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis.
Dellon ES; Peterson KA; Murray JA; Falk GW; Gonsalves N; Chehade M; Genta RM; Leung J; Khoury P; Klion AD; Hazan S; Vaezi M; Bledsoe AC; Durrani SR; Wang C; Shaw C; Chang AT; Singh B; Kamboj AP; Rasmussen HS; Rothenberg ME; Hirano I
N Engl J Med; 2020 Oct; 383(17):1624-1634. PubMed ID: 33085861
[TBL] [Abstract][Full Text] [Related]
10. Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis.
Youngblood BA; Brock EC; Leung J; Falahati R; Bochner BS; Rasmussen HS; Peterson K; Bebbington C; Tomasevic N
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31465299
[TBL] [Abstract][Full Text] [Related]
11. Treatment Trends for Eosinophilic Esophagitis and the Other Eosinophilic Gastrointestinal Diseases: Systematic Review of Clinical Trials.
Visaggi P; Ghisa M; Barberio B; Maniero D; Greco E; Savarino V; Black CJ; Ford AC; de Bortoli N; Savarino E
Dig Liver Dis; 2023 Feb; 55(2):208-222. PubMed ID: 35654734
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapies for Eosinophilic Gastrointestinal Disorders.
Lucendo AJ; López-Sánchez P
BioDrugs; 2020 Aug; 34(4):477-493. PubMed ID: 32472465
[TBL] [Abstract][Full Text] [Related]
13. A Case Series on the Use of Dupilumab for Treatment of Refractory Eosinophilic Gastrointestinal Disorders.
Patel N; Goyal A; Thaker A; Troendle D; Parrish C
J Pediatr Gastroenterol Nutr; 2022 Aug; 75(2):192-195. PubMed ID: 35666881
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging biologic therapies targeting eosinophilic disorders.
Pitlick MM; Li JT; Pongdee T
World Allergy Organ J; 2022 Aug; 15(8):100676. PubMed ID: 35983569
[TBL] [Abstract][Full Text] [Related]
15. Update on Emerging Pharmacologic Therapies for Patients With Eosinophilic Esophagitis.
Syverson EP; Hait E
Gastroenterol Hepatol (N Y); 2022 Apr; 18(4):207-212. PubMed ID: 35505944
[TBL] [Abstract][Full Text] [Related]
16. Current state of biologics in treating eosinophilic esophagitis.
Nhu QM; Aceves SS
Ann Allergy Asthma Immunol; 2023 Jan; 130(1):15-20. PubMed ID: 36243282
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapies for eosinophilic esophagitis.
Meek PD; Hemstreet B
Pharmacotherapy; 2023 Apr; 43(4):338-348. PubMed ID: 36840634
[TBL] [Abstract][Full Text] [Related]
18. Eosinophilic Esophagitis: the Potential Role of Biologics in its Treatment.
Choudhury S; Baker S
Clin Rev Allergy Immunol; 2020 Oct; 59(2):150-159. PubMed ID: 31175521
[TBL] [Abstract][Full Text] [Related]
19. Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab.
Dellon ES; Gonsalves N; Rothenberg ME; Hirano I; Chehade M; Peterson KA; Falk GW; Murray JA; Gehman LT; Chang AT; Singh B; Rasmussen HS; Genta RM
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):535-545.e15. PubMed ID: 34089846
[TBL] [Abstract][Full Text] [Related]
20. Eosinophilic Gastrointestinal Disorders.
Fahey LM; Liacouras CA
Pediatr Clin North Am; 2017 Jun; 64(3):475-485. PubMed ID: 28502433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
